Introduction
============

Pancreatic cancer is the twelfth most common malignancy, with 337,872 cases reported in 2012, and the seventh leading cause of cancer-associated mortality, with 330,391 mortalities reported in 2012, worldwide ([@b1-ol-0-0-9839]). Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. PDAC is the fourth leading cause of cancer-associated mortality in the USA ([@b2-ol-0-0-9839]); without any substantial improvement in curative therapies, it is anticipated to be the second leading cause of cancer-associated mortality by 2030 ([@b3-ol-0-0-9839]). Surgical resection is currently the only option to potentially achieve long-term survival ([@b4-ol-0-0-9839]). However, the 5-year survival rate is only \~10% following surgical therapy ([@b5-ol-0-0-9839]); therefore, postoperative adjuvant chemotherapy is being developed to improve prognosis. In the USA in 1985, the Gastrointestinal Tumor Study Group reported the use of postoperative adjuvant therapy for the first time ([@b6-ol-0-0-9839]). Later, in 2007, the CONKO-001 trial evaluated the use of gemcitabine ([@b7-ol-0-0-9839]). The effectiveness of postoperative S-1 adjuvant chemotherapy was revealed in Japan in 2016 ([@b8-ol-0-0-9839]). Nevertheless, the 5-year survival rate following surgery and adjuvant chemotherapy remains at only \~20% ([@b5-ol-0-0-9839],[@b9-ol-0-0-9839]). Due to postoperative quality of life degradation and other factors, there are a number of problems that result in insufficient adjuvant chemotherapy. Therefore, the importance of neoadjuvant therapy has recently been the focus of numerous studies ([@b10-ol-0-0-9839]). Treatment options for PDAC will diversify in the future and it will be necessary to make the optimal choice of therapy.

PDAC is postulated to lead to systemic metastasis, which is accompanied by an accumulation of various gene mutations ([@b11-ol-0-0-9839],[@b12-ol-0-0-9839]). However, which gene mutations are associated with clinicopathological prognostic factors is not clear. By identifying gene mutations that are associated with prognostic factors, there is a possibility that the range of treatment options will be increased. We previously reported that the preoperative carbohydrate antigen 19-9 (preCA19-9) level and the dissected peripancreatic tissue margin (DPM) were independent prognostic factors in PDAC ([@b13-ol-0-0-9839]). To date, it has repeatedly been reported that a positive margin and CA19-9 are prognostic factors in a univariate manner ([@b14-ol-0-0-9839]--[@b16-ol-0-0-9839]). However, each previous study included different clinicopathological factors and multivariate prognostic analysis revealed different sets of independent prognostic factors. To the best of our knowledge, our previous study was the first to report that the two factors can be simultaneously evaluated as independent prognostic factors ([@b13-ol-0-0-9839]). Analysis that combines these important prognostic factors may be useful in clinical management. However, our previous study had limitations, including a small sample size and follow-up period.

The aims of the current study were to validate the prognostic relevance of preCA19-9 and DPM as independent prognostic factors in primary PDAC and to clarify the associations between predictive factors and gene mutation status.

Materials and methods
=====================

### Registration of patients

From January 1986 to December 2013, 161 patients (median, 65; range 38--88), including 85 male and 76 female patients, with histologically confirmed PDAC underwent a pancreatectomy with D0-D3 lymph node dissection at the Department of Surgery, Kitasato University Hospital (Kanagawa, Japan). Patients with histological variants, including mucinous cystic adenocarcinoma, intraductal papillary adenocarcinoma, acinar cell carcinoma and endocrine carcinoma were excluded from the study. Preoperative workup included an ultrasonography, computed tomography, endoscopic retrograde pancreatography, endoscopic ultrasonography and magnetic resonance cholangiopancreatography to evaluate primary and metastatic tumor sites.

The preoperative serum CA19-9 levels were investigated immediately prior to surgery, avoiding the effects of obstructive jaundice and/or inflammation of the biliary duct. The recommended upper limit of a normal CA19-9 level is 37 U/ml, when CA19-9 levels are determined and defined from the standard deviations of healthy individuals. CA19-9 levels were determined using a chemiluminescent enzyme immunoassay kit (LUMIPLSE G; cat. no., CA19-9-N) obtained from Fujirebio US, Inc. (Malvern, PA, USA).

The surgical resection tissues were obtained from pancreaticoduodenectomy (n=39), pylorus-preserving pancreaticoduodenectomy (n=74), distal pancreatectomy (n=43) and total pancreatectomy (n=5). Partial resection of the portal vein was performed if the surgeon observed tumor invasion of the portal vein. Intraoperative pathologic assessment of the proximal or distal pancreatic margins was performed using frozen-tissue sections. If the pancreatic margin was positive for cancerous cells, further resection of the pancreas was performed. The present study was approved by the Institutional Review Board for Observation and Epidemiological Study, Kitasato University Medical Ethics Organization (approval no. B18-017; Kanagawa, Japan). All patients agreed to the use of their samples in scientific research and written informed consent was obtained from all patients.

### Pathological investigation

All histological and other clinicopathological factors were judged independently and blindly by histopathologists, and all histopathologic factors from the Japanese classification system (JCS) version 6 ([@b17-ol-0-0-9839]) were obtained from medical records. In the current study, stage was determined according to the 6th edition of the International Union Against Cancer (UICC) tumor-node-metastasis classification ([@b18-ol-0-0-9839]). Assessment of cancer infiltration at the surgical margin was evaluated according to the JCS, as DPM, pancreatic cut end margin or bile duct cut end margin. According to the National Comprehensive Cancer Network guideline ([@b19-ol-0-0-9839]), the surgical margin was defined as a superior mesenteric artery (SMA) margin, posterior margin, portal vein groove margin, portal vein margin, pancreatic margin or pancreatic surface and bile duct margin. Details of the DPM included the SMA margin, posterior margin and portal vein groove margin. Surgical margin-positive was defined as tumor cells present in the dissection surface, as judged by histopathologists. When requested by a pathologist, the gene mutation was investigated using non-radioisotopic single-strand conformation polymorphism (SSCP) from each DNA sample (n=97).

### DNA examination and search for the mutated K-ras gene using SSCP

For simultaneous DNA analysis, the previously described protocols were conducted ([@b20-ol-0-0-9839],[@b21-ol-0-0-9839]). Briefly, this consisted of five steps. Firstly, to prevent cross-contamination, small sections of fresh solid tissue were sampled by scraping with disposable bamboo combs, which are 3×3×120 mm rods made of bamboo with a spatula like ends. Secondly, one-step DNA extraction with lysis buffer containing proteinase K, Nonidet P-40 and Tween 20 was performed. Subsequently. polymerase chain reaction (PCR) was performed with each gene primer presented in [Table I](#tI-ol-0-0-9839){ref-type="table"} and the conditions presented in [Table II](#tII-ol-0-0-9839){ref-type="table"}. Next, SSCP analysis with polyacrylamide gels was performed, and detection was achieved by silver staining. In this analysis, mutated bands were evident at 1:64 dilutions of the mutated alleles.

### Follow-up and postoperative therapy

A total of 108 patients (67%) received empirical adjuvant therapy; this consisted of 105 patients who received chemotherapy and 3 patients who received radiotherapy. Another 23 patients (14%) received therapy for remnant tumor; specifically 22 patients who received chemotherapy and 1 patient who received radiotherapy. A number of chemotherapy regimens consisted of 5-fluorouracil (5-FU)-based chemotherapy, including 5-FU only (n=3), 5-FU/cisplatin (n=9) or 5-FU/Adriamycin/mitomycin-C/nimustine hydrochloride (n=2) by venous, portal or arterial infusion. Other chemotherapy regimens included tegafur/uracil (n=11), 5′-deoxy-5-fluorouridine (n=3) or TS-1 (n=3) as oral therapy, or mitomycin-C (n=7). In addition to gemcitabine (n=83) or gemcitabine+TS-1 (n=6) by venous or arterial infusion. Radiotherapy consisted of 1.8 Gy per day to a total dose of 50 Gy. Routine follow-up consisted of physical examination, laboratory studies and computed tomography imaging at 3- to 4-month intervals for the first 2 years, at 6-month intervals for years 3 to 5, and followed by annual follow-ups from thereon. Only the first sites of recurrence were recorded.

### Statistical analysis

Continuous variables were compared using the Student\'s t-test and nominal variables were compared using Pearson\'s chi-square test. The Kaplan-Meier method was used for disease-specific survival (DSS) analysis and the difference in survival rate was assessed by log-rank test ([@b22-ol-0-0-9839]). DSS was measured from the date of surgery to the date of mortality or last follow-up. Mortality associated with causes other than PDAC were not counted in this measurement. The variables that demonstrated prognostic potential suggested by univariate analysis (P\<0.05) were subjected to multivariate analysis with a Cox proportional hazards model. Propensity scores were matched using a caliper width of 0.2 multiplied by the standard deviation of values that was calculated by a logistic regression analysis. A receiver operating characteristic (ROC) curve was generated using JMP software v.11.0 (SAS institute, Cary, NC, USA) and the area under the curve (AUC) was used to optimize the best cut-off value. The associations between *K-ras* gene mutation and prognostic factors were examined with the Student\'s t-test. P\<0.05 was considered to indicate a statistically significant difference. All statistical analysis was performed using JMP software v.11.0.

Results
=======

### Patients\' characteristics and univariate prognostic analysis in PDAC

The first aim of the current study was to validate the prognostic relevance of preCA19-9 and DPM, which have previously been identified as independent prognostic factors in PDAC ([@b12-ol-0-0-9839]). The characteristics of 161 patients with PDAC and the univariate prognostic factors are summarized in [Table III](#tIII-ol-0-0-9839){ref-type="table"}. Significant prognostic factors included lymphatic permeation factor (ly; P=0.036), vascular permeation factor (v; P=0.0087), tumor differentiation (P=0.0037), intrapancreatic nerve invasion factor (ne; P=0.00025), retropancreatic tissue invasion factor (RP; P=0.0053), portal venous system invasion factor (PV; P=0.0133), extrapancreatic nerve plexus invasion factor (PL; P=0.0004), arterial system invasion factor (A; P=0.0019), preCA19-9 level (P\<0.0001), DPM (P\<0.0001) and UICC 6th stage (P\<0.0001). Arterial invasion was composed of pT4 (celiac artery or superior mesenteric artery; n=2) and non-pT4 (splenic artery; n=3). By increasing the number of patients from the previous pilot study ([@b13-ol-0-0-9839]), several pathological factors, which are not UICC staging factors, including ly, v, ne, RP, PV and A, were newly identified as univariate prognostic factors in PDAC.

### Multivariate Cox proportional hazards model in PDAC

The ten variables that exhibited prognostic potential identified by univariate prognostic analysis, including ly, v, tumor differentiation, ne, RP, PV, PL, A, preCA19-9, DPM and UICC 6th stage, were subjected to multivariate analysis. This analysis revealed that preCA19-9 \[P=0.0002, relative risk (RR)=2.8\], DPM positive (P=0.0002, RR=2.4), PV (P=0.01, RR=2.0) and A (P=0.035, RR=3.3) were the remaining prognostic factors independent of UICC stage (P=0.0015; [Table III](#tIII-ol-0-0-9839){ref-type="table"}).

Similar to previous studies ([@b23-ol-0-0-9839],[@b24-ol-0-0-9839]), preCA19-9 and DPM were identified as independent prognostic factors. The Kaplan-Meier curves of each factor are presented in [Fig. 1A](#f1-ol-0-0-9839){ref-type="fig"} for UICC stage, [Fig. 1B](#f1-ol-0-0-9839){ref-type="fig"} for PreCA19-9 and [Fig. 1C](#f1-ol-0-0-9839){ref-type="fig"} for DPM. Notably, all DPM-positive patients succumbed to the disease within 5 years, while a number of patients with preCA19-9 levels \>37 U/ml were alive with no recurrence after five years.

In addition, survival outcomes for the combination of preCA19-9 and DPM are presented in [Table III](#tIII-ol-0-0-9839){ref-type="table"} and [Fig. 1D](#f1-ol-0-0-9839){ref-type="fig"}. The prognosis of patients with PDAC was sub-classified into four groups (A, B, C and D) according to preCA19-9 and DPM (group A, preCA19-9 \>37 U/ml and DPM-positive; group B, preCA19-9 \>37 U/ml and DPM-negative; group C, preCA19-9 \<37 U/ml and DPM-positive; and group D, preCA19-9 \<37 U/ml and DPM-negative). Of note, group D demonstrated the best clinical outcome and included long-term survivors (10/30) of PDAC ([Fig. 1D](#f1-ol-0-0-9839){ref-type="fig"}).

### Prognostic relevance of DPM-positive status in PDAC following propensity score matching

A DPM-positive status may be the best indicator of highly aggressive tumor characteristics in PDAC; therefore, a risk model for DPM prediction was generated by logistic regression analysis. The clinicopathological factors analyzed were as follows: age, gender, ly, v, ne, RP, PV, A, PL, UICC stage and preCA19-9. Using this prediction model, an ROC curve was generated and presented in [Fig. 2A](#f2-ol-0-0-9839){ref-type="fig"} (AUC=0.80) and the propensity score (PS) to predict DPM was calculated. The density distribution of PS was analyzed between DPM-positive and DPM-negative patients, and a notable difference in the PS distribution was identified between the groups ([Fig. 2B](#f2-ol-0-0-9839){ref-type="fig"}). The matching of PS was performed by logit exchange. The logit exchange scores of the matched cases between both DPM-positive and DPM-negative cases were presented linearly in a scatter plot ([Fig. 2C](#f2-ol-0-0-9839){ref-type="fig"}). The logit exchange scores of the matched cases between DPM-positive and DPM-negative were distributed in Kernel density estimation differently from the unmatched cases ([Fig. 2D](#f2-ol-0-0-9839){ref-type="fig"}, left panel), as compared with the differential ranges prior to matching ([Fig. 2D](#f2-ol-0-0-9839){ref-type="fig"}, right panel). Following matching, no significant differences were identified for factors potentially affecting DPM between DPM-positive and DPM-negative cases ([Table IV](#tIV-ol-0-0-9839){ref-type="table"}). Notably, the factors identified to be associated with DPM positive were RP and RL, and these factors were corrected by score matching. As a result, DPM was demonstrated as a robust prognostic factor in PDAC (P=0.0008; [Fig. 2E](#f2-ol-0-0-9839){ref-type="fig"}).

Subsequently, initial recurrent sites were investigated in DPM-positive patients with PDAC. Among the 60 DPM-positive patients, 52 recurrences were identified. Liver metastases were the most prevalent in 21 patients (35%), followed by lymph node metastases in 13 patients (22%), peritoneal dissemination in 5 patients (8%), lung metastasis in 1 patient (35%), nerve plexus of the SMA in 9 patients (15%) and remnant pancreas in 3 patients (5%).

### Molecular association of DPM with mutational status of K-ras and p53 genes in PDAC

Subsequently, the associations of DPM with the mutational status of *K-ras* and *TP53* genes in PDAC were investigated. For *K-ras* gene mutation, 96 patients with PDAC were investigated. *K-ras* gene mutation was identified in 42 patients (44%), among whom 34 patients possessed mutations in exon1 (codon 12 or 13). The Kaplan-Meier curve was generated according to *K-ras* gene mutation status (P=0.043 by the log-rank test and P=0.0047 by the Wilcoxon test; [Fig. 3A](#f3-ol-0-0-9839){ref-type="fig"}). Since DPM has been cited as a poor prognostic factor in the present results, univariate analysis was performed for factors associated with DPM status ([Table V](#tV-ol-0-0-9839){ref-type="table"}). RP (P\<0.001), PL (P=0.0003) and *K-ras* gene mutation status (P=0.0002) were significantly associated with DPM-positive status. Multivariate analysis confirmed that RP (P=0.037), PL (P=0.026) and *K-ras* gene mutation status (P=0.0004) remained as independent factors of DPM-positive statue. A significant association was identified between DPM and *K-ras* gene mutation status ([Fig. 3B](#f3-ol-0-0-9839){ref-type="fig"}). DPM-positive patients had a *K-ras* gene mutation in 66.7% (26/39) of cases, while DPM-negative patients exhibited a *K-ras* gene mutation in 28.1% (16/57) of cases. For the *TP53* gene mutation, 67 patients with PDAC were examined and a *TP53* gene mutation was identified in 14 (20.9%). Of these, 6 patients were DPM-positive, and no significant difference was identified with regard to DPM status (P=0.9275).

Discussion
==========

PDAC is one of the most fatal forms of human malignancy and exhibits a poor 5-year survival rate even following curative resection and postoperative adjuvant chemotherapy ([@b5-ol-0-0-9839]). The present study indicated that long-term survivors following pancreatectomy can be predicted by a combination of clinicopathological factors, including preCA19-9 and DPM, which were prognostic factors independent of the cancer stage. These factors have been repeatedly reported in previous studies, therefore, they have been highly validated. However, to the best of our knowledge, no studies have analyzed a combination of these factors. In the current study, patients negative for both preCA19-9 and DPM (n=30) demonstrated a 5-year DSS of 68.5% following surgery, with 25 of the patients undergoing postoperative adjuvant chemotherapy. This finding recapitulated and validated our previous study ([@b13-ol-0-0-9839]) and such prognostic information may be useful in the development of optimal treatment strategies for PDAC.

The most established biomarker for PDAC diagnosis and prognosis is preCA19-9 ([@b14-ol-0-0-9839],[@b23-ol-0-0-9839]--[@b28-ol-0-0-9839]). Notably, preCA19-9 level could provide preoperative information and serve as a preoperative prognostic factor potentially able to affect the choice of treatment strategy, including the administration of neoadjuvant therapy. The current study determined that a pancreatectomy should be considered for patients with a low preCA19-9 level, while those with a high level of preCA19-9 tend to exhibit a poorer prognosis and may require neoadjuvant therapy prior to surgery to improve their survival rate. Previously, preoperative chemoradiation has been demonstrated to be a promising strategy to treat aggressive pancreatic cancer, including borderline resectable pancreatic cancer ([@b10-ol-0-0-9839]). The present study supports this novel promising therapeutic strategy for patients with PDAC and a high level preCA19-9.

By contrast, since DPM is a pathological factor, it cannot be preoperatively informative and preoperative prediction of future recurrence by DPM status is impossible. However, the present study demonstrated that DPM could accurately predict long-term survivors of PDAC following surgery, in combination with preCA19-9. Notably, all cases of DPM-positive PDAC inevitably succumbed to the disease; therefore, DPM status may indicate the tumor aggressiveness of PDAC and reflect specific molecular features.

To the best of our knowledge, the current study was the first to demonstrate that *K-ras* gene mutation is significantly associated with DPM-positive status, compared with DPM-negative status. *K-ras* gene mutation in the resected margin of PDAC has been reported to be a marker representing a poor prognosis ([@b29-ol-0-0-9839],[@b30-ol-0-0-9839]). In the present study, *K-ras* gene mutation was an independent predictor for DPM-positive status in multivariate analysis. Supporting these results, PDAC clones with mutated *K-ras* gene have previously been demonstrated to be persistently present in the retroperitoneal margin. *K-ras* gene mutation has been identified in pancreatic intraepithelial neoplasia, which is a precursor lesion ([@b31-ol-0-0-9839]). In addition, a previous study that used high-resolution analysis reported \>90% of cases have *K-ras g*ene mutation in PDAC tumors ([@b32-ol-0-0-9839],[@b33-ol-0-0-9839]). By contrast, but similar to our studies, conventional methods to investigate *K-ras* gene mutation have been widely reported. In a recent meta-analysis ([@b34-ol-0-0-9839]), the frequencies of *K-ras* gene mutations were reported to range from 47 to 88%. In the present study, the low rate of *K-ras* gene mutation is considered to be influenced by component rates of a small number of tumor cells mixed with a large number of stromal cells. Using conventional methods, it may be difficult to detect a small number of *K-ras* gene mutations in tumors, and the frequency of *K-ras* gene mutation therefore appears lower compared with that observed using high resolution analysis ([@b35-ol-0-0-9839]). An inducible Kras^G12D^ model elucidated that a precursor lesion with an activated K-ras signal transforms to carcinoma but a precursor lesion with an inactivated K-ras signal undergoes apoptosis ([@b36-ol-0-0-9839]). These findings may support the hypothesis that mutation of the *K-ras* gene is associated with tumor aggressiveness and micrometastases, which have the potential to disseminate systemically in DPM-positive patients, as observed in the current study.

The detection rate of *K-ras* gene mutation in the present study was low. However, previous studies have identified the frequencies of *K-ras* gene mutation in other cancer types using conventional methods and have repeatedly demonstrated standard values ([@b20-ol-0-0-9839],[@b37-ol-0-0-9839]--[@b40-ol-0-0-9839]). Therefore, it can be suggested that the present result reflects the conventional mutation rate of PDAC, which may represent dominant clones in the tumor tissues. With regard to positive association of DPM with *K-ras* gene mutation, validation was required for different patient sets, however the experiments performed in the current study could not be repeated due to technical reasons.

From 2014 to 2017, 96 patients with PDAC underwent a pancreatectomy at Kitasato University Hospital and 6 cases were examined for the *K-ras* gene mutation. Among the 6 patients with PDAC, *K-ras* gene mutation was identified in 2 (33%); patients with DPM-positive PDAC demonstrated a *K-ras* gene mutation in 50% (1/2) of cases, while DPM-negative patients exhibited a *K-ras* gene mutation in 25% (1/4) of cases. This result was consistent with the aforementioned results of the current study despite the small patient number. In the future, learning sets should be co-analyzed. Finally, as the recruitment period of the current study was long, numerous operators were involved in the study. Therefore, a number of factors could cause bias and affect the determination of DPM status. Periodical validation is required to confirm the results of the current study.

In conclusion, the present study validated and reiterated the prognostic relevance of DPM and preCA19-9 in patients with primary PDAC. This finding may be useful in the development of a novel treatment strategy for patients with PDAC and a poor prognosis. In addition, the current study revealed an association of DPM status with *K-ras* gene mutation in PDAC. This finding may facilitate the molecular understanding of PDAC and assist the development of molecular targeted therapy. Similar to other cancer types associated with a poor prognosis, multidisciplinary treatment, including preoperative treatment and aggressive surgery, and postoperative treatment, including molecular targeted therapy, should be adopted to further improve the prognosis of patients with PDAC. Thus, the present findings are important.
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![Disease-specific survival rates of pancreatic ductal adenocarcinoma. (A) Kaplan-Meier curve of Union for International Cancer Control stage. (B) Kaplan-Meier curve of preCA19-9 level. (C) Kaplan-Meier curve of DPM status. (D) Kaplan-Meier curve according to combinations of preCA19-9 level and DPM status. Group A, preCA19 \>37 U/ml and DPM-positive; group B, preCA19-9 \>37 U/ml and DPM-negative; group C, preCA19-9 \<37 U/ml and DPM-positive; and group D, preCA19-9 \<37 U/ml and DPM-negative. preCA19-9, preoperative carbohydrate antigen 19-9; DPM, dissected peripancreatic tissue margin.](ol-17-02-2141-g00){#f1-ol-0-0-9839}

![Propensity score matching method. (A) Receiver operating characteristic curve generated by multiplex logistic analysis demonstrated an AUC of 0.80. (B) Density distribution of propensity score. (C) Logit exchange scores of both DPM-positive and DPM-negative cases were aligned linearly in scatter plot. (D) Logit exchange scores of matched DPM-positive and DPM-negative cases were distributed in the same range in Kernel density estimation. (E) Kaplan-Meier curve of DPM following propensity score matching. DPM, dissected peripancreatic tissue margin; AUC, area under the curve.](ol-17-02-2141-g01){#f2-ol-0-0-9839}

![Associations between K-ras mutation and prognostic factors. (A) Comparison of disease-specific survival between *K-ras* gene wild-type and mutation. A significant difference in survival was identified using the Wilcoxon test (P=0.0047). (B) The association between DPM status and *K-ras* gene mutation was evaluated by the Student\'s t-test (P=0.0002). DPM, dissected peripancreatic tissue margin.](ol-17-02-2141-g02){#f3-ol-0-0-9839}

###### 

Primer sequences used for polymerase chain reaction.

  Gene    Exon   Forward sequence                Reverse sequence                Amplified fragment length, bp   Codons
  ------- ------ ------------------------------- ------------------------------- ------------------------------- ----------
  K-ras   1      5′-GACTGAATATAACTTGTGG-3′       5′-GCTATTGTTGGATCAATATTC-3′     108                             2--37
          2      5′-GATTCCTACAGGAAGCAAGT-3′      5′-TAATGGTGAATATCTTC-3′         185                             38--97
  TP53    5      5′-TTCCTCTTCCTGCAGTACTC-3′      5′-GCCCCAGCTGCTCACCATCGCTA-39   214                             125--186
          6      5′-GCCTCTGATTCCTCACTGATTG-3′    5′-AGTTGCAAACCAGACCTCAG-3′      157                             187--224
          7      5′-CCTCATCTTGGGCCTGTGTTATC-3′   5′-CAAGTGGCTCCTGACCTGGAGTC-3′   154                             225--261
          8      5′-CCTATCCTGAGTAGTGGTAA-3′      5′-GTCCTGCTTGCTTACCTCGC-3′      166                             262--306
          9      5′-GCCTCTTTCCTAGCACTGCC-3′      5′-CCAAGACTTAGTACCTGAAG-3′      101                             307--331

###### 

Polymerase chain reaction cycle conditions.

  Fresh samples                                       
  --------------------------------------------------- ----
  94°C 3 min                                          1
  52°C for 1 min, 72°C for 1 min, 94°C for 30 sec     2
  52°C for 45 sec, 72°C for 30 sec, 94°C for 20 sec   35
  52°C for 45 sec, 72°C for 3 min                     1

###### 

Univariate and multivariate prognostic analysis for 161 patients with PDAC who underwent pancreatectomy.

                                                                Univariate   Multivariate                                       
  ---------------------------------------------------- -------- ------------ -------------- ---------- ----------- ------------ ----------
  Age, years                                                                                                                    
    \<65/\>65                                          79/82    0.8          0.6--1.2       0.3150                              
  Sex                                                                                                                           
    Male/female                                        85/76    1.2          0.8--1.8       0.2628                              
  Lymphatic invasion                                                                                                            
    Absence/presence                                   22/139   1.8          1.1--3.5       0.0360     1.5         0.81--2.95   0.2109
  Venous invasion                                                                                                               
    Absence/presence                                   13/148   4            1.5--16.4      0.0087     1.6         0.56--6.91   0.4082
  Tumor differentiation                                                                                                         
    Well/other (moderate, poorly)                      137/24   2.1          1.2--3.4       0.0037     1.8         0.32--1.01   0.0563
  Intrapancreatic nerve invasionth                                                                                              
    Absence/presence                                   17/144   3.6          1.6--10.2      0.0025     2           0.87--6.1    0.1083
  Retropancreatic tissue invasion                                                                                               
    Absence/presence                                   62/99    1.8          1.2--2.7       0.0053     1.2         0.70--1.94   0.5635
  Portal venous system invasion                                                                                                 
    Absence/presence                                   131/30   1.8          1.1--2.9       0.0133     2           1.15--3.22   0.0143
  Extrapancreatic nerve plexus invasion                                                                                         
    Absence/presence                                   126/35   2.1          1.4--3.2       0.0004     1.5         1.15--3.22   0.1671
  Arterial system invasion                                                                                                      
    Absence/presence                                   156/5    3.8          1.3--8.6       0.0019     2.4         0.78--6.32   0.1173
  PreCA19-9 level, U/ml                                                                                                         
    \<37/\>37                                          39/122   3.5          2.1--6.4       \<0.0001   2.8         1.58--5.46   0.0003
  Dissected pancreatic tissue margin                                                                                            
    Negative/positive                                  101/60   2.9          2.0--4.3       \<0.0001   2.5         1.58--3.99   \<0.0001
  Stage^[b](#tfn2-ol-0-0-9839){ref-type="table-fn"}^                                                                            
    0--I                                               9        Reference                   \<0.0001   Reference                0.0032
    II                                                 122      9.6          2.1--169                  4.5         0.92--80.4   
    III                                                7        56.7         9.9--1067.6               13.5        2.0--268     
    IV                                                 23       30.5         6.3--547.8                9.4         1.81--173    
  PreCA19-9 and DPM combination                                                                                                 
    A; Over 37 U/ml and Positive                       51       Reference                   \<0.0001                            
    B; Over 37 U/ml and *N*egative                     71       2.6          1.7--3.9                                           
    C; \<37 U/ml and *P*ositive                        9        2.6          1.2--6.3                                           
    D; \<37 U/ml and *N*egative                        30       10.2         5.0--23.8                                          

According to log-rank test.

According to the 6th edition of the International Union Against Cancer staging system. RR, relative risk; CI, confidence interval; preCA19-9, preoperative carbohydrate antigen 19-9; DPM, dissected peripancreatic tissue margin.

###### 

Distribution of potential factors associated with DPM between DPM positive and negative cases prior to and following propensity score matching.

                                                       Prior to matching   Following matching                                                                                  
  ---------------------------------------------------- ------------------- -------------------- ------------------------------------------------------- ---------- ----------- ---------------------------------------------------
  Age^[a](#tfn3-ol-0-0-9839){ref-type="table-fn"}^     63.4±9.4            64.4±10.3            0.5172^[c](#tfn5-ol-0-0-9839){ref-type="table-fn"}^     64.1±9.1   64.7±10.4   0.81^[c](#tfn5-ol-0-0-9839){ref-type="table-fn"}^
  Sex                                                                                                                                                                          
    Male/female                                        30/29               55/46                0.6590^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     22/21      22/21       1.00^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  PreCA19-9 level, U/ml                                                                                                                                                        
    \<37/\>37                                          9/50                30/71                0.0400^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     8/35       10/33       0.59^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Stage^[b](#tfn4-ol-0-0-9839){ref-type="table-fn"}^                                                                                                                           
    0--I/II/III/IV                                     0/42/5/12           9/79/2/11            0.0097^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     0/33/2/8   0/35/2/6    0.84^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Lymphatic invasion                                                                                                                                                           
    Absence/presence                                   53/6                85/16                0.3056^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     38/5       37/6        0.75^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Venous invasion                                                                                                                                                              
    Absence/presence                                   56/3                91/10                0.2664^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     41/2       39/4        0.39^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Intrapancreatic nerve invasion                                                                                                                                               
    Absence/presence                                   56/3                87/14                0.00675^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^    40/3       40/3        1.00^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Retropancreatic tissue invasion                                                                                                                                              
    Absence/presence                                   51/8                48/53                \<0.0010^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^   35/8       32/11       0.44^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Portal venous system invasion                                                                                                                                                
    Absence/presence                                   12/47               18/83                0.6939^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     11/32      7/36        0.28^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Extrapancreatic nerve plexus invasion                                                                                                                                        
    Absence/presence                                   22/37               13/88                0.0003^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     9/34       11/32       0.61^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^
  Arterial system invasion                                                                                                                                                     
    Absence/presence                                   3/56                2/99                 0.2762^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^     2/42       1/41        0.56^[d](#tfn6-ol-0-0-9839){ref-type="table-fn"}^

Data are presented as the mean ± standard deviation.

According to the 6th edition of the International Union Against Cancer staging system.

According to Student\'s t-test.

Accroding to Pearson\'s chi-square test. DPM, dissected pancreatic tissue margin; preCA19-9, preorperative carbohydrate antigen 19-9.

###### 

Univariate and multivariate prognostic analysis for DPM.

                                          Univariate analysis   Multivariate analysis                                 
  --------------------------------------- --------------------- ----------------------- ---------- ----- ------------ --------
  Lymphatic invasion                                                                                                  
    Absence/presence                      53/6                  85/16                   0.3148                        
  Venous invasion                                                                                                     
    Absence/presence                      56/3                  91/10                   0.2820                        
  Intrapancreatic nerve invasion                                                                                      
    Absence/presence                      56/3                  87/14                   0.0822                        
  Retropancreatic tissue invasion                                                                                     
    Absence/presence                      51/8                  48/53                   \<0.0010   3.1   1.1--10.6    0.0373
  Portal venous system invasion                                                                                       
    Absence/presence                      12/47                 18/83                   0.6939                        
  Extrapancreatic nerve plexus invasion                                                                               
    Absence/presence                      22/37                 13/88                   0.0003     3.9   1.2--14.5    0.0264
  Arterial system invasion                                                                                            
    Absence/presence                      3/56                  2/99                    0.2762                        
  K-ras mutation                                                                                                      
    Negative/positive                     13/26                 41/16                   0.0002     5.2   2.07--14.2   0.0004

According to Pearson\'s chi-square test.

According to log-rank test. DPM, dissected pancreatic margin; CI, confidence interval.

[^1]: Contributed equally
